Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$172.95 ▼ -3.99
(-2.25%)
MKT CAP: $10.03B • VOL: 1.58M
52W L $101 52W H $199
RGEN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $154.5M | $98.3M | $133.6M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $55.2M | -$35.1M | $47.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $48.9M | -$25.5M | $35.6M |
| EBITDA (Normalized) | $74.0M | -$14.6M | $47.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $117.4M | $175.4M | $113.9M |
| Capital Expenditures (CapEx) | $23.5M | $25.7M | $0 |
| Free Cash Flow (FCF) | $93.9M | $149.7M | $113.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | 2.3% | -1.7% | 1.1% |
| Cash & Short-Term Equivalents | $566.0M | $757.4M | — |
| Total Debt (Short + Long Term) | $379.6M | $385.6M | $1.38B |
| Total Stockholders' Equity | $2.11B | $1.97B | $2.82B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RGEN.